A comparison of the growth-promoting, lipolytic, diabetogenic and immunological properties of pituitary and recombinant-DNA-derived bovine growth hormone (somatotropin)

Induction of lactation in dairy heifers: milk production, inflammatory and metabolic aspects

ABSTRACT The aim of this study was to evaluate the metabolic, inflammatory, and hepatic aspects, as well as the milk yield in heifers submitted to protocol for induction of lactation compared to primiparous cows. Sixty Holstein heifers were selected and enrolled into two groups: Control (n= 30), pregnant heifers and Induction heifers (n= 30), non-pregnant femeales, submitted to a lactation induction protocol. Blood samples were collected at: pre-lactation period (weeks -3, -2 and -1) and post-lactation period (weeks 1, 2 and 3), aiming to evaluate glucose, non-esterified fatty acids, paraoxonase-1, albumin, ALT, GGT and cortisol. The protocol efficiently induced lactation in all the heifers, which produced 74.54% of the total production of milk from primiparous cows. In the pre-lactation period, induced animals presented higher concentrations of non-esterified fatty acids than the Control heifers, and the opposite was observed in the post lactation period. In both moments albumin and ALT were lower in the Induction group, and paraoxonase-1 activity and GGT concentrations were higher, compared to the Control. Thus, lactation induction protocol is efficient to initiate milk production in dairy heifers with no considerable changes in energetic, metabolic and hepatic profile when compared to heifers in physiological lactation.

Different modes of food restriction and compensatory growth in double-muscled Belgian Blue bulls: plasma metabolites and hormones

The effects of different sequences of food restriction and fattening have been studied on plasma metabolites and hormones in double-muscled Belgian Blue bulls. Twenty animals were divided into five groups. The first group (control, CG) was given,ad libitum, a fattening diet based on sugar-beet pulp. In G2 and G3, fattening was interrupted after 103 and 187 days, respectively, by a period of food restriction lasting about 2 months during which the animals received a maintenance ration. They were finished with the same diet as CG. The last two groups, G4 and G5, received a limited amount of the restriction diet to support 0·5 and 0 kg gain per day, respectively, for 4 months, before being fattened as CG. Plasma glucose, alpha-amino nitrogen, non-esterified fatty acids, urea, creatinine, thyroxine (T4), 3, 3’, 5’-tri-iodothyroxine (T3), and insulin-like growth factor-1 (IGF-1) were measured in blood samples taken every 2 weeks. Plasma GH and insulin profiles were measured in serial blood samples obtained at three different times during growth. Animals that showed compensatory growth had lower plasma urea, associated with high levels of T3, T4 and IGF–1. Animals from G2 and G3 failed to show compensatory growth. In Belgian Blue bulls, compensatory growth is markedly affected when food restriction is severe or fattening interrupted.

The Placental Variant of Human Growth Hormone Reduces Maternal Insulin Sensitivity in a Dose-Dependent Manner in C57BL/6J Mice

The human placental GH variant (GH-V) is secreted continuously from the syncytiotrophoblast layer of the placenta during pregnancy and is thought to play a key role in the maternal adaptation to pregnancy. Maternal GH-V concentrations are closely related to fetal growth in humans. GH-V has also been proposed as a potential candidate to mediate insulin resistance observed later in pregnancy. To determine the effect of maternal GH-V administration on maternal and fetal growth and metabolic outcomes during pregnancy, we examined the dose-response relationship for GH-V administration in a mouse model of normal pregnancy. Pregnant C57BL/6J mice were randomized to receive vehicle or GH-V (0.25, 1, 2, or 5 mg/kg · d) by osmotic pump from gestational days 12.5 to 18.5. Fetal linear growth was slightly reduced in the 5 mg/kg dose compared with vehicle and the 0.25 mg/kg groups, respectively, whereas placental weight was not affected. GH-V treatment did not affect maternal body weights or food intake. However, treatment with 5 mg/kg · d significantly increased maternal fasting plasma insulin concentrations with impaired insulin sensitivity observed at day 18.5 as assessed by homeostasis model assessment. At 5 mg/kg · d, there was also an increase in maternal hepatic GH receptor/binding protein (Ghr/Ghbp) and IGF binding protein 3 (Igfbp3) mRNA levels, but GH-V did not alter maternal plasma IGF-1 concentrations or hepatic Igf-1 mRNA expression. Our findings suggest that at higher doses, GH-V treatment can cause hyperinsulinemia and is a likely mediator of the insulin resistance associated with late pregnancy.

Effects of bovine somatotropin administration on growth, physiological, and reproductive responses of replacement beef heifers

This experiment compared growth, body composition, plasma IGF-I and leptin, and reproductive development of beef heifers receiving or not recombinant bovine ST (BST) beginning after weaning until the first breeding season. Fifty Angus × Hereford heifers (initial BW = 219 ± 2 kg; initial age = 208 ± 2 d), weaned at approximately 6 mo of age, were assigned to the experiment (d 0 to 210). On d 0, heifers were ranked by initial BW and age and assigned to 1) treatment with BST or 2) saline control. Heifers assigned to the BST treatment received subcutaneous (s.c.) injections containing 250 mg of sometribove zinc whereas control heifers received a 5-mL s.c. injection of 0.9% saline every 14 d. Treatments were initiated on d 14 and last administered on d 196. Heifers were maintained on separate pastures harvested for hay the previous summer according to treatment and received grass and alfalfa hay at a rate to provide a daily amount of 7.0 and 1.0 kg of DM per heifer, respectively. Heifer shrunk BW was collected on d 1 and 211 for heifer ADG calculation. Blood samples were collected weekly from d 0 to 210 for determination of plasma progesterone to estimate puberty attainment as well as plasma concentrations of IGF-I and leptin in selected samples. On d 0, 63, 133, and 189, heifers were evaluated for intramuscular marbling, LM depth, and backfat thickness via real-time ultrasonography. No treatment effects were detected (P = 0.27) for heifer ADG (0.49 vs. 0.51 kg/d for control and BST heifers, respectively; SEM = 0.02). Mean backfat thickness was lesser (P < 0.01) in BST heifers compared with control cohorts (3.56 vs. 3.92 mm, respectively; SEM = 0.08). Heifers receiving BST had greater plasma IGF-I concentrations compared with control cohorts 7 d after treatment administration (treatment × day interaction; P < 0.01). Mean plasma leptin concentrations were lesser (P = 0.05) in BST heifers compared with control cohorts (1.82 vs. 2.03 ng/mL, respectively; SEM = 0.07). Onset of puberty was hastened in BST heifers compared with control cohorts (treatment × day interaction; P = 0.04). In summary, a greater proportion of BST heifers reached puberty during the experiment compared with control cohorts, despite lesser plasma leptin concentrations, backfat thickness, and similar ADG. Hence, circulating IGF-I was positively associated with hastened puberty attainment independently of growth rate, circulating leptin concentrations, and body fat content of replacement beef heifers.

The effects of dose and method of administration of biosynthetic bovine somatotropin on live-weight gain, carcass composition and wool growth in young lambs

Exogenous bovine pituitary somatotropin (GH) can influence markedly body composition in fattening lambs. However, neither the effects of biosynthetic somatotropin nor the effects of dose and method of administration have been reported. Fifty Dorset-cross lambs (female and castrated male) were given concentrate ad libitum and treated between 10 and 22 weeks of age with biosynthetic bovine somatotropin either dissolved in buffer and injected subcutaneously (s.c.) in proportion to body weight (0·025, 0·1 or 0·25 mg/kg per day), dissolved in buffer and continuously infused s.c. (0·1 mg/kg per day) or suspended in olive oil and injected s.c. (0·1 mg/kg per day), and compared with 10 untreated control lambs. Somatotropin had little effect on live-weight gain (controls = 228 g/day; final live weight 37 kg), food intake and food conversion efficiency, and only marginally increased the weight of muscle and bone dissected from the shoulder joint. The weights of the major fat depots in the abdominal cavity and of fat dissected from the shoulder joint were linearly related to dose of somatotropin (P < 0·001). Lambs given the highest dose had less visceral fat (1·18 v. 2·84 kg; P < 0·001) and proportionately less fat (285 v. 374 g/kg; P < 0·001) and more muscle (542 v. 447 g/kg) and bone (172 v. 149 g/kg; P < 0·001) in the shoulder joint than control lambs. There was a positive curvilinear relationship (P < 0·01) between clean wool growth (mid-side patch sample) and dose; lambs injected daily with 0·1 mg somatotropin per kg grew one-third more wool than control lambs. Method of administration affected plasma somatotropin profiles but had no significant influence on any of the responses measured. The anabolic actions of somatotropin may have been limited in this experiment by a low sodium concentration in the diet. It is concluded that the lipolytic/anti-lipogenic effect of somatotropin can occur in the absence of conditions conducive to the stimulation of muscle protein deposition and that the response is dose dependent but not influenced by method of administration of the hormone.

Board-invited review: the biology and regulation of preadipocytes and adipocytes in meat animals

The quality and value of the carcass in domestic meat animals are reflected in its protein and fat content. Preadipocytes and adipocytes are important in establishing the overall fatness of a carcass, as well as being the main contributors to the marbling component needed for consumer preference of meat products. Although some fat accumulation is essential, any excess fat that is deposited into adipose depots other than the marbling fraction is energetically unfavorable and reduces efficiency of production. Hence, this review is focused on current knowledge about the biology and regulation of the important cells of adipose tissue: preadipocytes and adipocytes.

Growth hormone size variants: changes in the pituitary during development of the chicken

There is considerable evidence for the existence of structural variants of growth hormone (GH). The chicken is a useful model for investigating GH heterogeneity as both size and charge immunoreactive-(ir) variants have been observed in the pituitary and plasma. The present study examined the size distribution of ir-GH in the pituitary gland of chicken, from late embryogenesis through adulthood. Pituitaries were homogenized in the presence of protease inhibitor, and the GH size variants were separated by SDS-PAGE, transferred by Western blotting, immunostained with a specific antiserum to chicken GH, and quantitated by chemiluminescence followed by laser densitometry (chemiluminescent assay). Under nonreducing conditions ir-GH bands of 15, 22, 25, 44, 50, 66, 80, 98, 105 and >110 kDa were observed. Both the relative proportion of the GH size variants and the total pituitary content varied with developmental stage and age. The proportion of the 15-kDa fragment was greatest in the embryonic stage, and then it decreased. The proportion of the monomeric 22-kDa form was lowest at 18 days of embryogenesis (dE) and highest at 20 dE. In contrast, the high MW forms (>/=66 kDa) were lowest in embryos, and they increased (P < 0.05) after hatching. The 22-, 44-, 66-, and 80-kDa forms were assayed for activity by radioreceptor assay following isolation by semipreparative SDS-PAGE. Only the 22-kDa GH variant showed radioreceptor activity. Under reducing conditions for SDS-PAGE, ir-GH bands of 13, 15, 18, 23, 26, 36, 39, 44, 48, 59 and 72 kDa were oberved, but most of the high MW form disappeared. There was a concomitant increase in the proportion of the monomeric band and of several submonomeric forms. The present data indicate that the expression, processing, and/or release of some if not all size variants are under some differential control during growth and development of the chicken.

Enhancement of the insulin antagonistic effect of porcine somatotropin in swine using a monoclonal antibody

A monoclonal antibody (mAb), PS-7.6, to porcine somatotropin (pST) significantly enhanced the growth responses to pST injections in hypophysectomized (hypox) rats but could not be tested in pigs because of the large quantity of antibody required for a growth trial. Because pST inhibits the hypoglycemic effects of insulin, an insulin tolerance test procedure was established to measure pST activity in jugular-catheterized pigs. Doses of 0, 30, 100, and 300 micrograms/kg per day of pST were split and administered subcutaneously (sc) in equal portions twice daily for 2 d. After a 17-hr fast, plasma samples were obtained at 10-min intervals for 30 min before an intravenous injection of insulin (0.08 IU/kg) and then for an additional 50 min. Because pST increased fasting plasma glucose concentrations, preinsulin glucose values were used as a covariate to adjust the postinsulin concentrations. pST caused a dose-dependent increase in resistance to the insulin injection in these pigs. The areas under the curves (AUC), for plasma glucose were 22.1, 29.0, 39.0, and 47.2 mg/dl per min for the 0, 30, 100, and 300 micrograms/kg pST doses, respectively. Because different doses of pST could be detected, the PS-7.6 enhancement of pST treatment was evaluated. In the first experiment, five pigs/group each received sc injections of either vehicle, pST (75 micrograms/kg; approximately 3.0 mg/d), pST (75 micrograms/kg) + PS-7.6 at 3.75 mg/kg, or pST (75 micrograms/kg) + PS-7.6 at 15 mg/kg for 2 d before the insulin test. The pST and PS-7.6 were combined and incubated for at least 1 hr at room temperature before being injected. The injection of pST alone did not significantly change insulin tolerance activity (23.1 vs. 21.1, AUC), but insulin resistance was enhanced when this dose of pST also included PS-7.6 (27.4 and 29.5, AUC, respectively; P < 0.05). In a second experiment, the effects of PS-7.6 and PS-4.2, a mAb that did not potentiate the pST-stimulated growth of hypox rats, were compared. The five pigs/treatment received either vehicle, pST (75 micrograms/kg), pST (75 micrograms/kg) + PS-7.6 (3.75 mg/kg), or pST (75 micrograms/kg) + PS-4.2 (3.75 mg/kg) for 2 d. The administration of pST increased the resistance to insulin (26.7 vs. 18.8, AUC; P < 0.01), which was markedly potentiated by PS-7.6 (54.3, AUC, P < 0.001) but not affected by PS-4.2 (27.6 AUC). The injection of PS-7.6 at 7.5 mg/kg without exogenous pST did not alter the sensitivity to insulin. These results indicate that PS-7.6, but not PS-4.2, enhanced the insulin antagonistic activity of pST in swine, suggesting that an enhancement of pST-stimulated growth would also occur in PS-7.6-treated pigs.

Modeling response to slow-releasing somatotropin administered at 3- or 4-week intervals

The purpose of this study was to develop a time-dependent model to account for the effects of recombinant bST in a slow-release formulation on short-term (between two consecutive injections) and long-term (baseline of the lactation curve) response of milk yield and composition. Observations on milk yield (n = 8234) and on milk composition (n = 1509) of 196 Holstein Friesian cows were recorded over 1 yr of trial. Treated cows were injected with somidobove at 3- or 4-wk intervals. Data were analyzed according to a model that included effect of treatment, parity, interaction, and the random effect of cow; two time-dependent covariables, obtained by the splitting of DIM, were included in the model to account for the effects of bST on short- and long-term responses of milk traits. Cyclical variations of milk yield, protein, and SCC content in the interval between two consecutive injections were detected. Recombinant bST administration also influenced the persistency of milk yield and protein content. Treatment of cows at 3- and 4-wk intervals increased yield by 20.6 and 12.6% over those of untreated cows. Nearly 60% of this increment was due to the short-term effect of bST. Milk composition response to bST was less noticeable.

Influence of adenosine or adrenergic agonists on growth hormone stimulated lipolysis by chicken adipose tissue in vitro

In vitro lipolysis by chicken adipose explants was stimulated by growth hormone (GH) or glucagon. Adenosine or the adenosine agonist, N6-phenylisopropyladenosine (PIA), inhibited GH stimulated lipolysis, the effect of adenosine not being observed in the presence or adenosine deaminase. Glucagon induced lipolysis was also reduced by PIA. It is suggested that adenosine may act by Gi linked to either adenylate cyclase (for glucagon) or the signal transduction mechanism for GH. Lipolysis was not stimulated by GH in the presence of phenylephrine (alpha 1 adrenergic agonist), isoproterenol (beta adrenergic agonist), adrenaline or glucagon. Although the presence of p-amino clonidine (alpha 2 adrenergic agonist) depressed basal lipolysis, a response to GH was still present. Either glucagon or beta-adrenergic agonists (isoproterenol, adrenaline) stimulated lipolysis. In both cases, GH attenuated the lipolytic response to these hormones, which act via a cyclic adenosine monophosphate signal transduction mechanism.

Purification, partial characterization, and heterologous radioimmunoassay of growth hormone (cGH) in red deer

Red deer growth hormone (cGH; 3.3 mg) was purified from an aqueous extract of seven pituitary glands (4.01 g wet weight) by preparative gel filtration on Sephadex G-100, gel filtration on Sephadex G-100 SF, and anion exchange chromatography on DEAE-Sepharose CL-6B. Purified cGH gave a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with a molecular weight under reducing conditions of 20,000 Da and gave a single peak on reverse-phase high-performance liquid chromatography. N-Terminal amino acid determination of 42 residues gave a sequence identical with those published for bovine and ovine GH. In a radioreceptor assay based on binding of iodinated recombinant bovine GH (rbGH) to liver microsomes prepared from a pregnant ewe, cGH was equipotent with an ovine GH (oGH) standard. In an oGH radioimmunoassay, cGH diluted in parallel with oGH and rbGH. Using this assay plasma GH concentrations were determined in adult nonpregnant red deer hinds over a 12-month period. There was a significant seasonality in plasma GH concentrations with concentrations consistently low between mid-May and mid-September. This is the period when voluntary food intake and liveweight gain are greatest. It is suggested that in the presence of low plasma GH concentrations nutrients may be diverted toward lipogenesis and hence promote fat deposition.

Metabolic effects of bovine growth hormone in the tilapia Oreochromis mossambicus

1. Bovine growth hormone (bGH) was injected into tilapia intramuscularly at a dose of 50 micrograms/100 g/day for a total of five injections. Control fish received saline instead. 2. The serum concentrations of amino acid and glucose were significantly higher and hepatic glycogen concentration and glycogen synthetase activity significantly lower in the bGH-treated fish than those in the control fish. 3. The serum concentrations of protein, lipid and cholesterol, and the hepatic concentrations of protein and lipid, remained unaltered after bGH treatment. 4. The results suggest that bGH exerts anti-insulin effects in tilapia.

Effects of feeding frequency and exogenous somatotropin on lipolysis, hormone profiles, and milk production in dairy cows

Effects of feeding frequency and exogenous bovine somatotropin on lactational performance and hormone profiles were examined with 12 multiparous Holstein cows. At 45 d postpartum, cows were assigned to one of two feeding systems. Concentrates were offered in two equal portions at 0800 and 1600 h or in 12 equal portions at 2-h intervals. Chopped alfalfa hay (2.6 kg/d) and barley silage (ad libitum) were fed at 0900 and 1500 h. At 136 d postpartum, cows within each feeding frequency were assigned in a single crossover design to injection of 30 mg of bST/d or solubilization vehicle. Feeding frequency did not influence any of the parameters measured nor did bST interact with feeding frequency. Somatotropin injection increased daily milk yield of cows by 4.4 kg and concentrations of fat and lactose in milk. Protein concentration and fatty acid composition of milk were not influenced by bST injection. Average plasma somatotropin concentrations were elevated threefold, peak concentrations were increased sevenfold, and concentrations at 48 h postinjection were 1.5 times control values. Plasma insulin concentrations were decreased by bST treatment. Results indicate that responses to short-term bST injection are not influenced by feeding frequency.

Growth, body composition, hormonal and metabolic status in lambs treated long-term with growth hormone

The effect of long-term (10 weeks) treatment with growth hormone (GH) was investigated in twin lambs, one sibling being a control and the other treated with GH (0.1 mg/kg live weight per d). The lambs were fed on a concentrate-grass cube (9:1 w/w) diet at a daily rate of 40 g fresh weight/kg live weight. The average daily live-weight gain of the GH-treated lambs was 36% greater than that of the controls (307 v. 225 g/d, P less than 0.01). The carcass composition of the GH-treated lambs changed: fat content was decreased (P less than 0.01) and protein content was increased (P less than 0.05) when expressed relative to carcass dry matter. The absolute weights and the weights when expressed relative to fleece-free empty body of some muscles were significantly increased in GH-treated lambs. The mean retention times of both particulate- and liquid-phase components of the digesta were unchanged by GH treatment, when calculated for the rumen or for the entire gastrointestinal tract. The feed conversion ratio was significantly greater (P less than 0.01) in GH-treated lambs compared with controls. Nitrogen retained per g N intake was also significantly increased (P less than 0.05) by GH treatment. Plasma urea concentrations were decreased (P less than 0.05) and glucose concentrations were increased (P less than 0.01) in GH-treated lambs, whereas non-esterified fatty acid concentrations were unchanged. Plasma insulin and total insulin-like growth factor-1 concentrations progressively increased in GH-treated lambs as treatment time continued. They were significantly correlated after week 4 of treatment. Two types of hepatic GH-binding site were detected, with high and low affinities for GH. The capacities of both binding sites were significantly increased (P less than 0.05) in GH-treated lambs when expressed per unit microsomal protein but, when expressed per liver, only the capacity of the high-affinity site was increased.

Response to metabolic challenges in early lactation dairy cows during treatment with bovine somatotropin

Milk production is increased in lactating cows treated with bovine somatotropin (bST) because a greater portion of absorbed nutrients are partitioned for milk synthesis. This homeorhetic action may be caused by alterations in response of key tissues to homeostatic signals. To examine this theory, acute metabolic challenges were administered to 8 multiparous Holstein cows (61 +/- 2 days postpartum) receiving daily subcutaneous injections of pituitary-derived bST (26.3 mg) or excipient during two 14-day treatment periods (crossover experimental design). Treatment with bST increased milk yield 12%. Feed intake did not change so that net energy balance decreased (+ .5 vs. -4.3 Mcal/day). Plasma concentrations of nonesterified fatty acids (NEFA) were chronically elevated in bST-treated cows, consistent with energy balance differences. However, baseline concentrations of glucose, insulin, and glucagon in plasma did not differ. On the last 3 days of treatment, individual metabolic challenges were administered via jugular cannulas: epinephrine (700 ng/kg BW), glucose (250 mg/kg BW), insulin (1.0 micrograms/kg BW), and glucagon (175 ng/kg BW). Plasma glucose was reduced after the insulin challenge to a lesser extent during bST treatment. In bST-treated cows, the increase in plasma NEFA in response to epinephrine was greater, and NEFA concentrations were lowered to a greater extent after insulin and glucose challenges. Glucose, insulin, and glucagon removal rates were not altered, nor was plasma glucose response to epinephrine or glucagon challenges. Treatment of lactating cows with bST primarily altered the response of adipose tissue to homeostatic signals which affect lipid metabolism.

Effect of bovine growth hormone on incorporation of [14C]acetate into lipids by co-cultures of bovine mammary, liver, and adipose tissue explants

Incorporation of [14C]acetate into lipids was measured in 24 hr co-cultures of mammary, liver and adipose tissue from Holstein cows at 53, 210 and 318 d of lactation in the presence or absence of bovine growth hormone. Little (less than 1%) of the labeled lipids appeared in the media relative to that incorporated into the tissue. In mammary tissue, incorporation of [14C]acetate was highest into triglycerides (16,298 cpm/mg mammary tissue), followed by phospholipids (1,887 cpm), free fatty acids (1,252 cpm), diglycerides (708 cpm), free cholesterol (360 cpm) and monoglycerides (93 cpm). Bovine growth hormone did not increase incorporation of [14C]acetate when mammary or adipose tissue were incubated separately. However, in the presence of liver and adipose tissue, bovine growth hormone significantly increased the incorporation of [14C]acetate into triglycerides, diglycerides, free fatty acids and free cholesterol by mammary tissue. These results suggest that bovine growth hormone acts on mammary tissue indirectly through liver and adipose tissue to increase lipid synthesis. This mechanism may play a role in the action of bovine growth hormone in vivo to increase milk and milk fat production.

Antilipogenic but not lipolytic effects of recombinant DNA-derived bovine somatotropin treatment on ovine adipose tissue; variation with genetic type

1. Lambs from three breeds (East Friesland, Oxford and Texel) were treated with recombinant DNA-derived bovine somatotropin (BST) at 0.05, 0.10, 0.20 mg/kg per day and fat metabolism assessed in subcutaneous adipose tissue biopsy samples. 2. BST treatment decreased adipose cell volume, fatty acid synthesis and acylglycerol glycerol synthesis but did not alter lipolytic rates (basal or noradrenaline-stimulated). 3. Genetic type influenced metabolism in a number of ways, most notably East Friesland lambs had lower fatty acid esterification rates and responded poorly to BST in terms of reduced lipogenesis as compared to the Oxford and Texel lambs. 4. Blood urea concentration was decreased by BST treatment suggesting increased nitrogen retention. 5. These results emphasise the role of somatotropin as an inhibitor of adipose tissue lipogenesis but cast further doubt on a physiological role in regulating lipolysis.

The effect of human growth hormone therapy on skinfold thickness in growth hormone-deficient children

Skinfold thickness (ST) was measured in 43 children with various forms of growth hormone (GH) deficiency during the first year of GH therapy. The average (and SEM) initial ST, expressed as standard deviation score (SDS) was 1.17 (0.25) for subscapular, 0.63 (0.18) for triceps, and 0.40 (0.21) for biceps ST. During therapy the average decrease is 1 SD. Children in the pubertal age group and those with partial GH deficiency showed smaller decreases. A larger decrease of triceps ST was associated with lower GH and insulin peaks, and lower age, bone age and initial weight-for-height. Some correlations between ST decrease and growth response in the first year were significant, but still too low to allow of reliable predictions. The same was true for other clinical parameters. These data indicate that a chronic lack of GH leads to unequal fat distribution, possibly due to different sensitivities to GH in the trunk and extremities. The variability of ST responses to GH therapy limits clinical applications.

Somatotropin antagonism of insulin-stimulated glucose utilization in 3T3-L1 adipocytes

It is well established that somatotropin (GH) antagonizes insulin action in vivo and that supraphysiologic concentrations of GH frequently result in insulin resistance and glucose intolerance. However, the demonstration of an anti-insulin activity by GH in vitro has been difficult. This study, therefore, set out to determine whether cultures of 3T3-L1 adipocytes could be used to examine the anti-insulin activity of GH. The ability of insulin to stimulate glucose utilization by 3T3-L1 adipocytes increases approximately five-fold during the first 4 days following treatment of the cells with a differentiation medium. It was found that glucose utilization in 3T3-L1 adipocytes is regulated in a reciprocal fashion by insulin and GH. Bovine or human GH directly inhibit up to 50% of insulin-stimulated [14C]-glucose incorporation into lipids in a concentration-dependent manner. The 3T3-L1 sensitivity to GH appears to be at the maximum (50% inhibition of an insulin response) immediately following removal of the cells from the differentiation medium and remains essentially constant during the subsequent 4 days. The GH inhibition of insulin action does not appear to be due GH enhancement of cellular degradation of insulin, competitive binding of GH to the insulin receptor, or GH-induced decrease in cell number. The 3T3-L1 adipocyte system appears to be a sensitive and reliable in vitro model with which to study the molecular mechanisms involved in both GH antagonism of insulin action and development of hormone responsiveness during cellular differentiation into adipocytes.

Nocturnal regulation of free fatty acids in healthy young and elderly men

To determine the effects of age on nocturnal fuel regulation, we measured spontaneous plasma glucose and free fatty acid (FFA) levels as well as counterregulatory hormones in healthy young (n = 9, mean age 26 +/- 3 years) and old (n = 10, mean age 69 +/- 3 years) men from midnight to 8 AM. FFA levels rose from midnight (660 +/- 80 mEq/L for young subjects, 545 +/- 55 mEq/L for old) to a peak mean level of 866 +/- 110 mEq/L at 3 AM in young and 713 +/- 120 mEq/L at 1:30 AM in old (P less than .05). FFA levels declined thereafter for both groups. FFA levels were lower in older subjects (P less than .05) but integrated glucose (P less than .05) and insulin (P less than .05) levels were higher. FFA levels were inversely related to integrated insulin (r = -0.46, P less than .05) and glucose concentrations (r = -0.66, P less than .05). Integrated insulin levels were significantly higher in older subjects, which may explain the lower FFA levels as may lower growth hormone levels in the older subjects. While fasting glucose responsivity to endogenous insulin is impaired in healthy older men, the FFA response appears to be preserved.

Nonesterified fatty acids and glucose in lactating dairy cows: diurnal variations and changes in responsiveness during fasting to epinephrine and effects of beta-adrenergic blockade

To examine whether the typical nightly rise of nonesterified fatty acids in high yielding dairy cows is due to enhanced sympathoadrenal activity, the beta-adrenergic blocker, propranolol, was infused from 1800 to 0805 h. Concentrations of nonesterified fatty acids continuously increased, whereas those of glucose and insulin decreased. Nonesterified fatty acid concentration decreased within minutes in response to concentrate feeding, starting at 0700 h, in association with an increase of insulin and glucose. In a second experiment, adrenaline (.82 mumol/kg/min) was infused from 1800 to 1810 h, 0600 to 0610 h, and 0600 to 0610 h on the 1st, 2nd and 3rd d. After the second infusion, food was withdrawn for 23 h. Concentrations of adrenaline increased similarly. Nonesterified fatty acids and glucose responses were higher during the second than the first infusion. During fasting, nonesterified fatty acid concentrations increased, whereas glucose and insulin concentrations decreased. During the third infusion nonesterified fatty acids responses were unchanged, whereas glucose responses were decreased. Thus, the nightly rise of nonesterified fatty acids was not the consequence of enhanced beta-adrenergic activity. Responses of glucose and nonesterified fatty acids to adrenaline exhibited diurnal differences. Responses of glucose to adrenaline were reduced within 1 d of fasting, whereas those of nonesterified fatty acids were not altered.

Recombinant-DNA-derived bovine growth hormone from Escherichia coli. 1. Demonstration that the hormone is expressed in reduced form, and isolation of the hormone in oxidized, native form

The isolation of bacterially synthesized, recombinant-DNA-derived, bovine growth hormone (r-bGH) with native structure is described. The r-bGH is found in insoluble form, in a pellet fraction, after cell breakage and centrifugation. Cell envelope components (protein, lipid, endotoxin) and nucleic acids are selectively removed from the pellet fraction by an EDTA/lysozyme/deoxycholate extraction. We demonstrate that the r-bGH is largely reduced until solubilized using 6 M guanidine/HCl. Air oxidation is then carried out, in the presence of the guanidine/HCl. The oxidation results in a mixture of about one-third disulfide-linked oligomers and two-thirds oxidized monomer. The latter may include some incorrectly oxidized material, but appears to be mostly correctly oxidized. The oxidized monomer is isolated by gel filtration in the presence of guanidine/HCl. Subsequent guanidine/HCl removal leads to refolded, oxidized r-bGH. All steps in the procedure, in particular the oxidation and refolding steps, can be carried out at relatively high protein concentrations.

Physiology of the somatotropic axis with particular reference to the ruminant

The physiology of growth hormone and the insulin-like growth factors are reviewed with particular reference to the dairy industry. Growth hormone secretion in the ruminant is pulsatile in nature and nutritional factors have a major impact on its secretion. Isolation of growth hormone-releasing factor has allowed further progress in understanding the mechanisms underlying growth hormone release. The receptors appear to be under active endocrine and metabolic control, and nutritional influences on the somatotropic axis are in large part mediated through changes in somatotropic receptors. The mode of action of growth hormone to induce acute metabolic affects and lipolysis remains to be resolved, but there is increasing evidence that its anabolic actions are mediated by the insulin-like growth factors. Recent studies of measurement of insulin-like growth factor-1 and -2 in the ruminant and the role of growth hormone, nutrition, insulin, and sex steroids in their regulation are reviewed. The relative role of the two factors and the multiple forms of their receptors remain to be resolved. It is well-documented that growth hormone is galactopoietic. The evidence that this effect is largely due to enhanced nutrient supply to the mammary gland is not convincing. Effects of growth hormone are indirect and may be mediated by the insulin-like growth factors. The potential is considerable for manipulating the growth hormone insulin-like growth factor axis to enhance lactation.

Somatotropin and lactation

Somatotropin, which can now be produced by biotechnology, could have an enormous impact on the dairy industry. Milk yield has been increased up to 40% with daily injections of somatotropin. Cows adjust their nutrient intake to support this increase. Somatotropin does not adversely affect cows' health, although all studies to date have been for less than one complete lactation. The search for a single biochemical or physiological event to account for the effects of somatotropin on milk production is elusive. Coordinated changes in many tissues and physiological processes occur to support the increases in the synthesis of lactose, fat, and protein in the mammary gland. Changes in the irreversible loss and oxidation rates of two key metabolites, glucose and free fatty acids, can quantitatively account for increases in lactose and milk fat during the short-term administration of somatotropin. Similarly, feed intake and live weight changes can account for increases in milk production in the longer experiments. Parallels between physiological changes that occur during somatotropin administration and differences between genetically high and lower yielding cows are highlighted, and the rates of improvement that can be expected from various new technologies are quantified. Existing data on the safety of somatotropin to both the consumer and the animal are evaluated.

Some biological activities of recombinant DNA-derived growth hormone on plasma metabolite concentrations in domestic fowl

The biological activity of recombinant-DNA-derived chicken growth hormone (rcGH) has been examined in young broiler cockerels, by determining its effects on plasma concentrations of glucose, free fatty acids and alpha-amino nitrogen. A single injection of rcGH increased plasma glucose, which remained high for several hours, whereas daily treatment with rcGH for 1 week had no effect on basal plasma glucose concentrations but blunted the glucose response to a further rcGH challenge. Plasma free fatty acids were also promptly increased following acute rcGH treatment, and chronic exposure to rcGH again attenuated this response. The effects of rcGH on plasma alpha-amino nitrogen were more variable. The stress of repeated blood sampling tended to reduce alpha-amino nitrogen, and after rcGH, an increase relative to vehicle-injected controls was seen in both acute and chronically-treated birds. These data suggest that rcGH has both hyperglycaemic and lipolytic activity in chickens, and may also increase amino acid availability.

Reoxidation of reduced bovine growth hormone from a stable secondary structure

In order to determine solution conditions appropriate for reoxidizing reduced bovine growth hormone (bGH), we have examined the possibility of using a particular denaturant concentration to poise the secondary and tertiary structure of the reduced protein in a stable, nativelike state. It was envisioned that the structure of the reduced molecule would differ from that of the final oxidized molecule solely by the absence of disulfide bonds. Dilution of concentrated samples of reduced and unfolded protein from 6.0 M guanidine into 4.5 M urea followed by air oxidation indicated it was possible to induce refolding and reoxidation to an oxidized monomeric species in high yield (approximately 90%). The choice of solution conditions was based on comparison of urea equilibrium denaturation data for native oxidized protein to those for completely reduced protein and to protein in which sulfhydryl groups had been either partially or completely reduced and subjected to modification with iodoacetamide or methyl methanethiolsulfonate. The denaturation behavior of these species supports the existence of equilibrium folding intermediates for bovine growth hormone and demonstrates that chemical modification of the protein is capable of inducing differences in the denaturation behavior of these intermediates. The changes in the protein absorption spectrum and helix-related circular dichroism signal, along with direct titration of protein sulfhydryl groups, indicated that the refolding/reoxidation of bGH is a multistate process. The ordered nature of the kinetic changes in these probes during reoxidation indicates that disulfide formation is a sequential process, with little mispairing in 4.5 M urea, and that it proceeds through one or more obligatory kinetic folding events. The equilibrium denaturation behavior of the oxidized molecule and the various chemically modified forms, together with the reoxidation data, indicated that the protein maintains a high degree of secondary structure without intrachain disulfide bonds. The formation of these disulfide bonds is a discrete process which occurs after a framework of protein secondary structure is established.

Evidence for differential binding of growth hormones to membrane and cytosolic GH binding proteins of rabbit liver

The existence of three GH binding proteins in rabbit liver membranes has been adduced from binding studies with a panel of monoclonal antibodies. Immunologically cross-reactive analogues of 'type 2' binding proteins were shown to exist in rabbit liver cytosol and in affinity purified receptor from liver microsomes. We now report differences in the binding of human and ovine GH with respect to two antigenic determinants on the 'type 1' GH binding protein. The discovery of these differences has enabled the detection of cross-reactive analogues of both binding protein types '1' and '2' in liver cytosol and in affinity purified preparations from liver membranes. These findings show a close structural relationship between the pool of cytosolic GH binding proteins and those present in the membranes; and differential ligand binding to, as well as absolute ligand selection by GH binding proteins, which could reflect the ability of GH to trigger a range of biological responses either through different receptors or differential interaction with particular receptor subtypes.

Acute effects of metabolic hormones in swine

Many metabolic hormones (glucagon, hydrocortisone, corticosterone, TSH, thyroxine and triiodothyronine) did not stimulate porcine adipose tissue lipolysis in vitro. Growth hormone and ACTH stimulated lipolysis at high concentrations, in the presence of theophylline. Insulin inhibited lipolysis. Infusion of metabolic hormones with measurement of plasma free fatty acid and glycerol concentrations, purportedly indicative of in vivo lipolysis, indicated that glucagon and somatotropin had no effect, adrenocorticotropin increased and insulin depressed plasma concentrations of the metabolites. Overall, the in vitro predicts the in vivo response. There were exceptions, e.g. adrenocorticotropin moderately increased plasma metabolites but had little effect in vitro.

Studies of the putative transforming protein of the type I human T-cell leukemia virus

The putative transforming protein of the type I human T-cell leukemia virus (HTLV-1) is a 40-kilodalton protein encoded by the X region and is termed p40XI. On the basis of both subcellular fractionation techniques and immunocytochemical analysis, it is now shown that p40XI is a nuclear protein with a relatively short half-life (120 minutes). It is synthesized de novo in considerable quantities in a human T-cell line infected with and transformed by the virus in vitro, and it is not packaged in detectable amounts in the extracellular virus.